'Order for 9M rapid HIV tests'

Trinity Biotech (Nasdaq: TRIB) received a 9 million-unit order for its WHO-prequalified TrinScreen HIV rapid test, with fulfillment planned in Q4 2025 and Q1 2026. The company reported Q3 2025 revenue $14.3M (+32% vs Q2 2025), gross profit $6.5M, gross margin rising to 45.2%, and Adjusted EBITDA $0.5M (vs -$2.1M in Q2 2025). Trinity cites WHO approval for outsourced manufacturing and expects further Adjusted EBITDA improvement in Q1–Q2 2026 as its Comprehensive Transformation Plan advances.

https://www.stocktitan.net/news/TRIB/trinity-biotech-awarded-a-major-order-for-9-million-trin-screen-hiv-k5mfskafcnme.html